The N.N. Alexandrov National Centre beings Phase II case-control clinical trial of its immune-oncology agent called Elenagen.
Inoperable late-stage cancer patients with triple-negative breast cancer, ovarian cancer, stomach cancer or prostate cancer will be randomized and then subsequently receive either standard chemotherapy or chemotherapy combined with Elenagen. For each disease, the experimental and control groups will be compared for time to disease progression, overall survival, as well as tumor regression and the dynamics of clinical conditions. One can also expect a reversal of a tumor grade to an operable stage, which would make the tumor surgically removable.
What is Elenagen?
Elenagen was developed by CureLab Oncology, Inc., a Boston-based biotech startup which provided the product to Belarussian college. Aldevron, Inc. (Fargo, ND) was the contract research manufacturer of the product. Dr. Alex Shneider, CEO of CureLab Oncology reported “Although in the coming year we are planning to start Phase II clinical trials of Elenagen in breast cancer and ovarian cancers in the U.S. and multiple other countries, it is very important for us to begin with Belarus, the country which was the most hit by Chernobyl.
Thanks to Those Who Donated
Professor Surgey Krasny, MD, PhD, DSc, deputy director of the Alexandrov National Cancer Centre and corresponding member of the Belarus National Academy of Sciences, reported, “We are very thankful to our colleagues from NYU and MD Anderson Cancer Centers who donated their ideas and expertise, went with us through multiple iterations of the clinical protocol, and helped to create the final version which we will now implement in our studies. Without their generous assistance and continuous support, we would not be where we are now.”
The study has been unanimously approved by the Belarus Ministry of Health. The team of clinical investigators conducting the trial in Belarus will maintain constant contact and consistently exchange information with their colleagues in the U.S. and EU, and Israel serving as observers and scientific co-authors of the study.
About N.N. Alexandrov National Cancer Centre
The state institution “N.N. Alexandrov National Cancer Centre” is the leading oncological institution in the Republic of Belarus, by offering the full range of services in the field of diagnosis, treatment, and education for patients and doctors from all over the world. All these services are free for citizens of the Republic of Belarus. The Centre includes 4 scientific departments, 10 scientific laboratories, 17 in patient and 15 diagnostic divisions, as well as 1,750 employees, of who 389 hold either MDs or MD/PhD degrees and 12 hold the rank of professor. The patients and trainees benefit from the state-of-the-art equipment and state-of-the-art modern clinical laboratory facilities.
Surgey Krasny, MD, PhD, DSc, deputy director of the Alexandrov National Cancer Centre
Anton Khorau, M.D., PhD